Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968940 · ClinicalTrials.gov registry record · Phase 2
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02968940 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT02968940, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to test how safe and effective treatment with the combination of Avelumab and radiation is for IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
Interventions
- BIOLOGICAL Avelumab
- RADIATION Hypofractionated radiation therapy (HFRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968940
The ClinicalTrials.gov registry entry for NCT02968940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT02968940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968940 about?
NCT02968940 is a clinical study titled "Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma". The purpose of this study is to test how safe and effective treatment with the combination of Avelumab and radiation is for IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
What is the current status of trial NCT02968940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-03-17. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT02968940?
The interventions under investigation include: Avelumab (BIOLOGICAL), Hypofractionated radiation therapy (HFRT) (RADIATION).
Who is sponsoring clinical trial NCT02968940?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.